Benign Prostatic Hyperplasia Market - Growth, Trends, and Forecast (2019 - 2024)

The Market is segmented by Drug Type (Alpha-Blockers, 5- Alpha-Reductase Inhibitors (5-Aris), Alpha-Adrenergic Blockers, Phosphodiesterase-5 Enzyme Inhibitors, and Other Drug Types), Distribution Channels, and Geography

Market Snapshot

Benign Prostatic Hyperplasia-1
Study Period:

2016-2024

Base Year:

2018

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

8.5%

Key Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

  • The benign prostatic hyperplasia market is expected to register a CAGR of nearly 8.5% during the forecast period, 2019-2024.
  • Benign prostatic hyperplasia (BPH) also known as benign prostatic hypertrophy is characterized by the unusual propagation of the prostatic cells, which causes difficulties, like urinary retention and infection of the urinary tract. It is most common among aging men. These are the reasons driving the market growth,
  • Benign prostatic hyperplasia (BPH) is being accepted as a growing health problem among elderly men.
  • With the rising population of aged men, the degree of the problem is projected to rise multifold over the next few years. As per a publication in the United States Census Bureau (2018), the population of people aged 65 and above in the United States is likely to increase drastically between 2016 and 2060. By 2030, one in five US citizens is expected to be 65 years and older, crossing 78.0 million, out of the total population.
  • The diseased population is also significantly rising in the emerging markets. The advancements in early diagnosis of the disease and geriatric population are driving the demand for products to cure benign prostatic hyperplasia.

Scope of the Report

As per the scope of the report, benign prostatic hyperplasia is a medical condition involving enlargement of the prostate gland and it is highly prevalent in males.

 It is a non-cancerous growth of the prostate gland originating from the uncontrolled expansion of prostate cells. The common symptoms associated with BPH include frequent urination, urine initiation difficulties, weak urinary system, and inability to empty the urinary bladder.

 Currently, medications are the common way to treat men with mild to moderate BPH.

By Drug Type
Alpha-Blockers
5- Alpha-Reductase Inhibitors (5-Aris)
Alpha-Adrenergic Blockers
Phosphodiesterase-5 Enzyme Inhibitors
Other Drug Types
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Alpha-Blockers is Expected to Hold Largest Share of Global Benign Prostatic Hyperplasia Market, Over the forecast period

  • Alpha-blockers help in relaxing the muscle of the prostate and the bladder neck, which allow urine to flow easier.
  • Alpha-blockers work quickly and are usually the first line of treatment for men with mild to moderate symptoms. For instance, α1 blockers are recommended in the clinical guidelines for BPH in Japan, as first-line drug therapy for lower urinary tract symptoms (LUTS) associated with BPH.
  • Moreover, for people with high blood pressure and BPH, alpha-blockers are the ideal treatment line for both the conditions.
  • Owing to these factors, alpha-blockers accounted for the largest market share in the global benign prostatic hyperplasia market.
Benign Prostatic Hyperplasia-2

To understand key trends, Download Sample Report

North America Region Holds the Largest Market Share of Benign Prostatic Hyperplasia Market

North America dominates the market owing to the high prevalence of BPH and other associated lower urinary tract symptoms. Several studies in past one era have reported a significant percentage of men in the US, aged between 45 and 80 years suffer from some type of lower urinary tract symptoms and most have some form of BPH symptoms. In addition, several hospitals across the US, and Canada have collaboration with the non-profit organization and companies such as GlaxoSmithKline in some of the projects to raise awareness and adequate resources for the treatment of urological disorders. Also, the rising geriatric population is bolstering the growth of the market. Thus, North America is a very lucrative market for the companies contributing to a large share of this market.

Benign Prostatic Hyperplasia-3

To understand geography trends, Download Sample Report

Competitive Landscape

  • Alpha-blockers help in relaxing the muscle of the prostate and the bladder neck, which allow urine to flow easier.
  • Alpha-blockers work quickly and are usually the first line of treatment for men with mild to moderate symptoms. For instance, α1 blockers are recommended in the clinical guidelines for BPH in Japan, as first-line drug therapy for lower urinary tract symptoms (LUTS) associated with BPH.
  • Moreover, for people with high blood pressure and BPH, alpha-blockers are the ideal treatment line for both the conditions.
  • Owing to these factors, alpha-blockers accounted for the largest market share in the global benign prostatic hyperplasia market.

Major Players

  1. Allergan PLC
  2. Astellas Pharma Inc.
  3. Boehringer Ingelheim
  4. Eli Lilly and Company
  5. Merck & Co., Inc.

* Complete list of players covered available in the table of contents below

Benign Prostatic Hyperplasia-4

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Geriatric Population

      2. 4.2.2 Growing Technological Advancements in Personalized Medicines

      3. 4.2.3 Rising Awareness Through Campaigns

    3. 4.3 Market Restraints

      1. 4.3.1 Rising Preference Toward Minimally Invasive Surgeries

      2. 4.3.2 Non-adherence of Patients to Pharmacological Therapy

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Drug Type

      1. 5.1.1 Alpha-Blockers

      2. 5.1.2 5- Alpha-Reductase Inhibitors (5-Aris)

      3. 5.1.3 Alpha-Adrenergic Blockers

      4. 5.1.4 Phosphodiesterase-5 Enzyme Inhibitors

      5. 5.1.5 Other Drug Types

    2. 5.2 By Distribution Channel

      1. 5.2.1 Hospital Pharmacies

      2. 5.2.2 Retail Pharmacies

      3. 5.2.3 Online Pharmacies

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Allergan PLC

      2. 6.1.2 Astellas Pharma Inc.

      3. 6.1.3 Boehringer Ingelheim

      4. 6.1.4 Eli Lilly and Company

      5. 6.1.5 GlaxoSmithKline PLC

      6. 6.1.6 Nymox Pharmaceutical Corporation

      7. 6.1.7 Pfizer Inc

      8. 6.1.8 Sanofi

      9. 6.1.9 Sophiris Bio Corp

      10. 6.1.10 Teva Pharmaceutical Industries Limited

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please Enter a Valid Message!


Complete your payment details below

Shipping & Billing Information

Payment Information